Australia Markets closed

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.8600-0.1900 (-3.76%)
At close: 04:00PM EDT
5.1000 +0.24 (+4.94%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.0500
Bid4.8600 x 1000
Ask7.7200 x 800
Day's range4.8400 - 5.1000
52-week range4.8400 - 24.2650
Avg. volume662,371
Market cap221.934M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-1.1070
Earnings date08 May 2023 - 12 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est26.17
  • GlobeNewswire

    PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

    Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023Enrolled first patient in combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab)Cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022 PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PMV

  • GlobeNewswire

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

    PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March. Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023)Format:Tumor Diagnostic Development Corporate PanelDate:W

  • Zacks

    Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?

    The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.